XsnQ...Sd1X

Latest insights

No insights yet

No market data

News feed

Moderna shares more than doubled after its personalized cancer vaccine cleared a late-stage melanoma trial

Moderna's personalized mRNA cancer vaccine intismeran met key goals in a Phase 3 melanoma trial when combined with Merck's Keytruda, sending $MRNA shares up more than 145% and exposing short sellers...

BSCN·2026-08-19 17:52:39 UTC

Comments

Comments are per language — only shown on this locale’s page.

Loading comments...